Other Information .
+Added: During the three months ended June 30, 2023, no director or officer of the Company adopted or terminated a " Rule 10b5-1 trading arrangement" or " non-Rule 10b5-1 trading arrangement" as each term is defined in Item 408(a) of Regulation S-K.
The exhibits listed on the Exhibit Index immediately preceding such exhibits, which is incorporated herein by reference, are filed or furnished as part of this Quarterly Report on Form 10-Q.
10 unchanged sentences
Second Amended and Restated Bylaws
+Added: Amended and Restated Lead DMD Product Manufacturing and Supply Agreement between Catalent Maryland, Inc.
+Added: and Sarepta Therapeutics Three, LLC
+Added: Exclusive License Agreement between the Research Institute at Nationwide Children's Hospital and Sarepta Therapeutics, Inc., dated October 8, 2018
+Added: First Amendment, dated May 29, 2019, to the Exclusive License Agreement between Research Institute at Nationwide Children's Hospital and Sarepta Therapeutics, Inc.
+Added: Second Amendment, dated July 11, 2023, to the Exclusive License Agreement between Research Institute at Nationwide Children's Hospital and Sarepta Therapeutics, Inc.
+Added: First Amendment to the Amended and Restated Lead DMD Product Manufacturing & Supply Agreement between Catalent Maryland, Inc.
+Added: and Sarepta Therapeutics Three, LLC
Certification of the Company’s Principal Executive Officer, Douglas S.
15 unchanged sentences
Indicates management contract or compensatory plan, contract or arrangement.
−Removed: * Identified information has been excluded from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.
+Added: * Certain identified information has been excluded from the exhibit.
** The Certifications attached as Exhibits 32.1 and 32.2 that accompany this Quarterly Report on Form 10-Q are not deemed filed with the SEC and are not to be incorporated by reference into any filings of Sarepta Therapeutics, Inc.
2 unchanged sentences
SAREPTA THERAPEUTICS, INC.
+Added: August 2, 2023
/s/ DOUGLAS S.
1 unchanged sentence
(Principal Executive Officer)
+Added: August 2, 2023
Executive Vice President, Chief Financial Officer
1 unchanged sentence
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.